PharmaLectures.com

Courses › Regulatory affairs by region › European Union: ASMF or CEP, the two roads into Europe for an API, and how to pick yours

European Union: ASMF or CEP, the two roads into Europe for an API, and how to pick yours

Your team picks the right European route for each active substance and files it once.

CEP and ASMF are the two ways an active substance maker can give European regulators the quality data for its API. A CEP, or Certificate of Suitability to the monographs of the European Pharmacopoeia, is issued by the EDQM after one central assessment, and each medicine application then cites the certificate. An ASMF, or Active Substance Master File, is filed with the authorities alongside each application, in an open part the customer sees and a restricted part that only regulators see. With this course, teams pick the right road.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • RA, QA, BDwho it is written for

Why CEP and ASMF training matters

A customer's marketing authorization application reaches the reviewer, and the Restricted Part of your master file leaves out a process detail. The deficiency letter lands. Your regulatory manager rewrites the answer while the customer waits, and the launch date moves.

What changes after this course

Your team chooses between the Active Substance Master File and the Certificate of Suitability before work starts, and drafts each part for the right reader. You hold a certificate for each learner and a training record for each person, ready for the next audit.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

CEP and ASMF training: what this course gives your people

Your regulatory team stops debating at the whiteboard. A new active substance comes in, and within the meeting they decide between the Active Substance Master File and the Certificate of Suitability, because they know what each route needs, what the European Pharmacopoeia monograph changes, and what your customer expects. The wrong dossier no longer gets drafted.

Quality assurance writes the Applicant's Part and the Restricted Part of the file with a clear line between them. Module 3 of the Common Technical Document is laid out right the first time, so validation questions stop arriving. Your partner gets what the assessor needs, and the synthesis details stay with the authority, protected by a letter of access that names one customer.

The site manager walks the floor with EudraLex Volume 4 Part II in mind, and the inspector finds the filed process and the running process match. When a change comes up, the team knows whether it needs a revision application for the certificate or a variation for the master file, and files it before the first batch.

Business development answers a partner's question about monographs, supply chain oversight or certificate status in the room, not by email next week. They explain how the European Directorate for the Quality of Medicines and HealthCare handles your certificate, how you audit suppliers, and why your file is safe to rely on.

Who needs CEP and ASMF training

  • Regulatory Affairs Manager

    A customer asks on Monday whether you will file a master file or a certificate. They answer with the criteria in hand, and the dossier work starts that day, not after a week of debate.

  • Quality Assurance Specialist

    The inspector asks to see how the filed process matches the plant. They open the records that EudraLex Volume 4 Part II expects, and the supplier audit file that proves oversight, without a hunt through folders.

  • Business Development Manager

    A prospective partner asks whether your certificate covers their route and what happens if your process changes. They answer in the meeting and name the pathway, the monograph and the update rules, so the partner sees a supplier who knows its file.

  • Head of Active Substance Manufacturing

    Production proposes a change to a reaction step. They check at once whether it needs a revision application or a variation, and plan the filing before the change reaches the line, so the certificate stays valid.

Roles: Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Decide between the Active Substance Master File and the Certificate of Suitability for a given substance, and write down the reason.
  2. Draft an Applicant's Part that gives a partner's assessor what they need while keeping the synthesis details out.
  3. Place the Restricted Part content in Module 3 of the Common Technical Document and write a letter of access for one named customer.
  4. Prepare a Certificate of Suitability application that answers the European Directorate's questions on the monograph and test results.
  5. Judge whether a manufacturing change needs a revision application, and file it before the change reaches the line.
  6. Check a site's daily practice against EudraLex Volume 4 Part II and fix the gaps before an inspector finds them.
  7. Plan a supplier audit of an active substance vendor and write the report an inspector can follow.

What the company gets

  • A customer's reviewer finds your active substance file complete, so the deficiency letter that holds up a launch is less likely to come from your side.
  • Your team chooses the master file or the certificate route in the first meeting, so no one drafts a dossier that has to be redone.
  • Inspectors get a straight answer on how the filed process matches the plant, and the records to prove it.
  • Partners and buyers hear a clear account of your certificate, your change handling and your supplier oversight from the person they ask.
  • Each learner holds a certificate, and you keep a training record per person to show an auditor who was trained and when.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

CEP and ASMF course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Apply Directive 2001/83/EC to what your active substance file must show

    • How to trace each data demand in an active substance dossier back to Directive 2001/83/EC.
    • Why your customer's marketing authorization application stands or falls on your active substance data.
    • The short list of documents that prove active substance quality to a European reviewer.
  2. 2Pick the Active Substance Master File or the Certificate of Suitability

    • When a Certificate of Suitability fits your substance, and when only a master file will do.
    • Why a substance without a European Pharmacopoeia monograph usually cannot take the certificate route.
    • What to do when your customer wants one route and your plant is set up for the other.
  3. 3Build your submission in Common Technical Document format

    • How to place each quality fact in Module 3 of the Common Technical Document where reviewers look for it.
    • The section headings that make a file read as complete before anyone opens the detail.
    • What to do when a customer asks you to restructure your file to match their own format.
  4. 4Draft the open part so partners see enough and your process stays private

    • How to give your customer's assessor enough to judge the substance without handing over your process.
    • The open part sections that stop follow-up questions before the first assessment round.
    • Why your partner must read the open part closely, and what they do with it.
  5. 5Shield your manufacturing secrets in the Restricted Part of your file

    • How to describe your synthesis in the Restricted Part so only the authority sees the detail.
    • Why the process in your file and the process on the floor must match, line by line.
    • How to write a letter of access that lets one named customer rely on your file and nobody else.
  6. 6Submit your dossier to the right authority and meet the timeline

    • How the Restricted Part reaches the authority while the open part goes through your customer.
    • What your customer must submit and when, so your file is not the reason the clock stops.
    • The dates in the assessment procedure where your answers are due, and how to prepare before they arrive.
  7. 7Get a Certificate of Suitability through the European Directorate's review

    • How the European Directorate for the Quality of Medicines and HealthCare reads your application.
    • The test results and monograph data that a certificate application must show up front.
    • What to do when a deficiency question arrives for the certificate and the answer needs plant data.
  8. 8Update your certificate before a process change puts it at risk

    • How to tell, before you implement it, whether a process change needs a revision application.
    • Why an unreported process change puts the certificate itself at risk of suspension or withdrawal.
    • The change-control entry that lets your production team flag a revision trigger before the first batch.
  9. 9Answer agency questions and pass the active substance site inspection

    • How to answer a deficiency letter point by point, with the evidence attached to each answer.
    • What an inspector compares when they walk your active substance plant against the filed dossier.
    • Why a serious inspection finding can put your certificate on hold and your customer's approval behind it.
  10. 10Apply EudraLex Volume 4 Part II on the active substance factory floor

    • How EudraLex Volume 4 Part II turns into daily checks your operators can run at the line.
    • The records an auditor expects to see when checking good manufacturing practice for a substance.
    • Why your customers must verify your good manufacturing practice status, and what you hand them.
  11. 11File post-approval variations as minor or major, and in the right order

    • How to sort a change into minor or major before you tell a single customer.
    • The route a master file change takes to reach the authority and the marketing authorization holders.
    • Which variations you may implement at once and which must wait for approval.
  12. 12Audit active substance suppliers so your oversight stands up to inspectors

    • How to plan a supplier audit that shows inspectors your oversight is continuous.
    • The quality system documents to read before you qualify a new active substance vendor.
    • Why a paper questionnaire alone does not qualify a supplier, and what the audit adds.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about CEP and ASMF training

What is a CEP certificate?

A CEP is a Certificate of Suitability to the monographs of the European Pharmacopoeia. The EDQM, part of the Council of Europe, issues it after assessing that the monograph adequately controls the quality of a substance from a given manufacturer, including its impurities. Applicants then cite the CEP in their marketing authorisation dossier instead of supplying the full active substance data. The EDQM can also inspect the manufacturing site.

When should an API maker choose an ASMF instead of a CEP?

A CEP is only possible for a substance described in a European Pharmacopoeia monograph, so a substance without a monograph needs an ASMF. An ASMF can also suit makers who supply few customers or who want the restricted part kept away from the applicant. A CEP saves work when many customers in many countries reference the same substance, because it is assessed once.

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for RA, QA, BD. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team